References
- Troidle L, Gorban-Brennan N, Kliger A, Finkelstein FO. Continuous peritoneal dialysis-associated peritonitis: a review and current concepts. Semin Dial 2003; 16: 428–37
- Vas S, Oreopoulos DG. Infections in patients undergoing peritoneal dialysis. Infect Dis Clin North Am 2001; 15: 743–74
- Slotnick IJ, Dougherty M. Further characterization of an unclassified group of bacteria causing endocarditis in man: Cardiobacterium hominis Gen. Et Sp. N. Antonie Van Leeuwenhoek 1964; 30: 261–72
- Steinberg JP, Del Rio C. Other Gram-negative bacilli. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Disease5th ed, GL Mandell, JE Bennett, R Dolin. Churchhill Livingstone, New York 2000; 2459–74
- Slotnick IJ. Cardiobacterium hominis in genitourinary specimens. J Bacteriol 1968; 95: 1175
- Wormser GP, Bottone EJ. Cardiobacterium hominis: review of microbiologic and clinical features. Rev Infect Dis 1983; 5: 680–91
- Das M, Badley AD, Cockerill FR, Steckelberg JM, Wilson WR. Infective endocarditis caused by HACEK microorganisms. Annu Rev Med 1997; 48: 25–33
- Francioli PB, Roussianos D, Glauser MP. Cardiobacterium hominis endocarditis manifesting as bacterial meningitis. Arch Intern Med 1983; 143: 1483–4
- Apisarnthanarak A, Johnson RM, Braverman AC, Dunne WM, Little JR. Cardiobacterium hominis bioprosthetic mitral valve endocarditis presenting as septic arthritis. Diagn Microbiol Infect Dis 2002; 42: 79–81
- Rechtman DJ, Nadler JP. Abdominal abscess due to Cardiobacterium hominis and Clostridium bifermentans. Rev Infect Dis 1991; 13: 418–9
- Keane WF, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, et al. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int 2000; 20: 396–411
- Zelenitsky S, Barns L, Findlay I, Alfa M, Ariano R, Fine A, et al. Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998. Am J Kidney Dis 2000; 36: 1009–13
- Kugler KC, Biedenbach DJ, Jones RN. Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms. Diagn Microbiol Infect Dis 1999; 34: 73–6